Moving forward in clinical trials for ALS: motor neurons lead the way please

Rosen, 1993, Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis, Nature, 362, 59, 10.1038/362059a0 Gurney, 1994, Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation, Science, 264, 1772, 10.1126/science.8209258 Gurney, 1997, The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies, J. Neurol. Sci., 152, S67, 10.1016/S0022-510X(97)00247-5 Ludolph, 2010, Guidelines for preclinical animal research in ALS/MND: a consensus meeting, Amyotroph. Lateral Scler., 11, 38, 10.3109/17482960903545334 Bensimon, 1994, A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group, N. Engl. J. Med., 330, 585, 10.1056/NEJM199403033300901 Lacomblez, 1996, Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lancet, 347, 1425, 10.1016/S0140-6736(96)91680-3 Barber, 2010, Oxidative stress in ALS: key role in motor neuron injury and therapeutic target, Free Radic. Biol. Med., 48, 629, 10.1016/j.freeradbiomed.2009.11.018 Benatar, 2007, Lost in translation: treatment trials in the SOD1 mouse and in human ALS, Neurobiol. Dis., 26, 1, 10.1016/j.nbd.2006.12.015 Bosco, 2010, Genetic determinants of amyotrophic lateral sclerosis as therapeutic targets, CNS Neurol. Disord. Drug Targets, 9, 779, 10.2174/187152710793237494 Habib, 2011, Emerging drugs for amyotrophic lateral sclerosis, Expert Opin. Emerg. Drugs, 16, 537, 10.1517/14728214.2011.604312 Kuzma-Kozakiewicz, 2011, New therapeutic targets for amyotrophic lateral sclerosis, Expert Opin. Ther. Targets, 15, 127, 10.1517/14728222.2011.542152 Pawlyk, 2010, Current nervous system related drug targets for the treatment of amyotrophic lateral sclerosis, Curr. Pharm. Des., 16, 2053, 10.2174/138161210791293024 Zinman, 2011, Emerging targets and treatments in amyotrophic lateral sclerosis, Lancet Neurol., 10, 481, 10.1016/S1474-4422(11)70024-2 Son, 2011, Conversion of mouse and human fibroblasts into functional spinal motor neurons, Cell Stem Cell, 9, 205, 10.1016/j.stem.2011.07.014 Benmohamed, 2011, Identification of compounds protective against G93A SOD1 toxicity for the treatment of amyotrophic lateral sclerosis, Amyotroph. Lat. Scler., 12, 87, 10.3109/17482968.2010.522586 Egawa, 2012, Drug screening for ALS using patient-specific induced pluripotent stem cells, Sci. Transl. Med., 4, 145ra104, 10.1126/scitranslmed.3004052 Sandoe, 2013, Opportunities and challenges of pluripotent stem cell neurodegenerative disease models, Nat. Neurosci., 16, 780, 10.1038/nn.3425 Berry, 2011, New considerations in the design of clinical trials for amyotrophic lateral sclerosis, Clin. Investig., 1, 1375, 10.4155/cli.11.127 Cudkowicz, 2010, Toward more efficient clinical trials for amyotrophic lateral sclerosis, Amyotroph. Lateral Scler., 11, 259, 10.3109/17482960903358865 Boillee, 2006, ALS: a disease of motor neurons and their nonneuronal neighbors, Neuron, 52, 39, 10.1016/j.neuron.2006.09.018 Robberecht, 2013, The changing scene of amyotrophic lateral sclerosis, Nat. Rev. Neurosci., 14, 248, 10.1038/nrn3430 Cozzolino, 2012, Amyotrophic lateral sclerosis: new insights into underlying molecular mechanisms and opportunities for therapeutic intervention, Antioxid. Redox Signal., 17, 1277, 10.1089/ars.2011.4328 Drachman, 2002, Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS, Ann. Neurol., 52, 771, 10.1002/ana.10374 Kiaei, 2006, Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis, J. Neurosci., 26, 2467, 10.1523/JNEUROSCI.5253-05.2006 Kriz, 2002, Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis, Neurobiol. Dis., 10, 268, 10.1006/nbdi.2002.0487 Van Den Bosch, 2002, Minocycline delays disease onset and mortality in a transgenic model of ALS, Neuroreport, 13, 1067, 10.1097/00001756-200206120-00018 Gurney, 1998, Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis, Neurology, 50, 62, 10.1212/WNL.50.1.62 Rothstein, 2005, Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression, Nature, 433, 73, 10.1038/nature03180 Kalmar, 2008, Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS, J. Neurochem., 107, 339, 10.1111/j.1471-4159.2008.05595.x Kieran, 2004, Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice, Nat. Med., 10, 402, 10.1038/nm1021 Crow, 2005, Manganese porphyrin given at symptom onset markedly extends survival of ALS mice, Ann. Neurol., 58, 258, 10.1002/ana.20552 Ito, 2008, Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice, Exp. Neurol., 213, 448, 10.1016/j.expneurol.2008.07.017 Petri, 2006, Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis, Neurobiol. Dis., 22, 40, 10.1016/j.nbd.2005.09.013 Otto, 2012, Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS, Amyotroph. Lateral Scler., 13, 1, 10.3109/17482968.2011.627589 Bowser, 2011, Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations, Nat. Rev. Neurol., 7, 631, 10.1038/nrneurol.2011.151 Ozdinler, 2011, Corticospinal motor neurons and related subcerebral projection neurons undergo early and specific neurodegeneration in hSOD1G93A transgenic ALS mice, J. Neurosci., 31, 4166, 10.1523/JNEUROSCI.4184-10.2011 Yasvoina, 2013, eGFP expression under UCHL1 promoter genetically labels corticospinal motor neurons and a subpopulation of degeneration-resistant spinal motor neurons in an ALS mouse model, J. Neurosci., 33, 7890, 10.1523/JNEUROSCI.2787-12.2013 Levine, 1999, Astrocytes interact intimately with degenerating motor neurons in mouse amyotrophic lateral sclerosis (ALS), Glia, 28, 215, 10.1002/(SICI)1098-1136(199912)28:3<215::AID-GLIA5>3.0.CO;2-C Gordon, 2011, How can we improve clinical trials in amyotrophic lateral sclerosis?, Nat. Rev. Neurol., 7, 650, 10.1038/nrneurol.2011.147 Kaspar, 2003, Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model, Science, 301, 839, 10.1126/science.1086137 Kaspar, 2005, Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis, Ann. Neurol., 57, 649, 10.1002/ana.20451 Vincent, 2004, IGF-I prevents glutamate-induced motor neuron programmed cell death, Neurobiol. Dis., 16, 407, 10.1016/j.nbd.2004.03.001 Ozdinler, 2006, IGF-I specifically enhances axon outgrowth of corticospinal motor neurons, Nat. Neurosci., 9, 1371, 10.1038/nn1789 Lai, 1997, Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group, Neurology, 49, 1621, 10.1212/WNL.49.6.1621 Borasio, 1998, A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group, Neurology, 51, 583, 10.1212/WNL.51.2.583 Sorenson, 2008, Subcutaneous IGF-1 is not beneficial in 2-year ALS trial, Neurology, 71, 1770, 10.1212/01.wnl.0000335970.78664.36 Bradley, 1995, A Phase I/II study of recombinant human brain-derived neurotrophic factor in patients with amytrophic lateral sclerosis, Ann. Neurol., 38, 971 1999, A controlled trial of recombinant methionyl human BDNF in ALS (Phase III), Neurology, 52, 1427, 10.1212/WNL.52.7.1427 Ochs, 2000, A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis, Amyotroph. Lateral Scler. Other Motor Neuron Disord., 1, 201, 10.1080/14660820050515197 Kalra, 2003, A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results, Amyotroph. Lateral Scler. Other Motor Neuron Disord., 4, 22, 10.1080/14660820310006689 Park, 2009, Growth factor-expressing human neural progenitor cell grafts protect motor neurons but do not ameliorate motor performance and survival in ALS mice, Exp. Mol. Med., 41, 487, 10.3858/emm.2009.41.7.054 Calvo, 2011, Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule, Orphanet. J. Rare Dis., 6, 10, 10.1186/1750-1172-6-10 Azzouz, 2004, VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model, Nature, 429, 413, 10.1038/nature02544 Klivenyi, 1999, Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis, Nat. Med., 5, 347, 10.1038/6568 Snow, 2003, Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice, Neuroscience, 119, 661, 10.1016/S0306-4522(03)00212-4 Groeneveld, 2003, A randomized sequential trial of creatine in amyotrophic lateral sclerosis, Ann. Neurol., 53, 437, 10.1002/ana.10554 Shefner, 2004, A clinical trial of creatine in ALS, Neurology, 63, 1656, 10.1212/01.WNL.0000142992.81995.F0 Danzeisen, 2006, Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride], J. Pharmacol. Exp. Ther., 316, 189, 10.1124/jpet.105.092312 Cudkowicz, 2011, The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis, Nat. Med., 17, 1652, 10.1038/nm.2579 Rudnicki, 2013, Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics, Amyotroph. Lateral Scler. Frontotemporal Degener., 14, 44, 10.3109/17482968.2012.723723 Yoshino, 2006, Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study), Amyotroph. Lateral Scler., 7, 241, 10.1080/17482960600881870 Orrell, 2006, AEOL-10150 (Aeolus), Curr. Opin. Investig. Drugs, 7, 70 Cudkowicz, 2008, Arimoclomol at dosages up to 300mg/day is well tolerated and safe in amyotrophic lateral sclerosis, Muscle Nerve, 38, 837, 10.1002/mus.21059 Lanka, 2009, Arimoclomol: a potential therapy under development for ALS, Expert Opin. Investig. Drugs, 18, 1907, 10.1517/13543780903357486 Fornai, 2008, Lithium delays progression of amyotrophic lateral sclerosis, Proc. Natl. Acad. Sci. U. S. A., 105, 2052, 10.1073/pnas.0708022105 Fornai, 2008, Lithium in ALS: from the bench to the bedside, Amyotroph. Lateral Scler., 9, 123, 10.1080/17482960802028197 Pizzasegola, 2009, Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice, Amyotroph. Lateral Scler., 10, 221, 10.1080/17482960902803440 Chio, 2010, Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial, Neurology, 75, 619, 10.1212/WNL.0b013e3181ed9e7c Aggarwal, 2010, Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial, Lancet Neurol., 9, 481, 10.1016/S1474-4422(10)70068-5 Zhang, 2011, Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis, Autophagy, 7, 412, 10.4161/auto.7.4.14541 Wang, 2012, Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43, Proc. Natl. Acad. Sci. U. S. A., 109, 15024, 10.1073/pnas.1206362109 Groeneveld, 2004, CGP 3466B has no effect on disease course of (G93A) mSOD1 transgenic mice, Amyotroph. Lateral Scler. Other Motor Neuron Disord., 5, 220, 10.1080/14660820410019530 Miller, 2007, Phase II/III randomized trial of TCH346 in patients with ALS, Neurology, 69, 776, 10.1212/01.wnl.0000269676.07319.09 Ryu, 2005, Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice, J. Neurochem., 93, 1087, 10.1111/j.1471-4159.2005.03077.x Li, 2000, Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model, Science, 288, 335, 10.1126/science.288.5464.335 Cudkowicz, 2006, Trial of celecoxib in amyotrophic lateral sclerosis, Ann. Neurol., 60, 22, 10.1002/ana.20903 Neymotin, 2009, Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis, Exp. Neurol., 220, 191, 10.1016/j.expneurol.2009.08.028 Stommel, 2009, Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial, Amyotroph. Lateral Scler., 10, 393, 10.3109/17482960802709416 Keller, 2011, Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice, Exp. Neurol., 228, 69, 10.1016/j.expneurol.2010.12.010 Gordon, 2007, Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial, Lancet Neurol., 6, 1045, 10.1016/S1474-4422(07)70270-3 Tortarolo, 2006, Glutamate AMPA receptors change in motor neurons of SOD1G93A transgenic mice and their inhibition by a noncompetitive antagonist ameliorates the progression of amytrophic lateral sclerosis-like disease, J. Neurosci. Res., 83, 134, 10.1002/jnr.20715 Bellingham, 2011, A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?, CNS Neurosci. Ther., 17, 4, 10.1111/j.1755-5949.2009.00116.x Scott, 2008, Design, power, and interpretation of studies in the standard murine model of ALS, Amyotroph. Lateral Scler., 9, 4, 10.1080/17482960701856300 Haddad, 2003, Riluzole attenuates spinal muscular atrophy disease progression in a mouse model, Muscle Nerve, 28, 432, 10.1002/mus.10455 Ishiyama, 2004, Riluzole slows the progression of neuromuscular dysfunction in the wobbler mouse motor neuron disease, Brain Res., 1019, 226, 10.1016/j.brainres.2004.06.002 Kennel, 2000, Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn), J. Neurol. Sci., 180, 55, 10.1016/S0022-510X(00)00423-8 Seok, 2013, Genomic responses in mouse models poorly mimic human inflammatory diseases, Proc. Natl. Acad. Sci. U. S. A., 110, 3507, 10.1073/pnas.1222878110 Molyneaux, 2007, Molecular development of corticospinal motor neuron circuitry, Novartis Found. Symp., 288, 3, 10.1002/9780470994030.ch2 Lemon, 2008, Descending pathways in motor control, Annu. Rev. Neurosci., 31, 195, 10.1146/annurev.neuro.31.060407.125547 Kawamura, 1981, Morphometric comparison of the vulnerability of peripheral motor and sensory neurons in amyotrophic lateral sclerosis, J. Neuropathol. Exp. Neurol., 40, 667, 10.1097/00005072-198111000-00008 Del Signore, 2009, Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice, Amyotroph. Lateral Scler., 10, 85, 10.1080/17482960802226148 Waibel, 2004, Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model, J. Neurol., 251, 1080, 10.1007/s00415-004-0481-5